Ligand Pharmaceuticals
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.6 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 117.71% +1.57pp
- Institutions
- 495 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 18 buys · 32 sells
| Name | Role | Stake |
|---|---|---|
| Todd Davis | Chief Executive Officer | 0.82% |
| Jason Aryeh | Independent Director | 0.54% |
| John Kozarich | Independent Chairperson | 0.21% |
| Stephen Sabba | Independent Director | 0.16% |
| Andrew Reardon | Chief Legal Officer | 0.16% |
| Octavio Espinoza | Chief Financial Officer | 0.14% |
| John LaMattina | Independent Director | 0.13% |
| Nancy Gray | Independent Director | 0.04% |
| Jason Haas | Independent Director | 0.02% |
| Martine Zimmermann | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | John Kozarich | Independent Chairperson | Intent to Sell (Form 144) | -500 | $325.00 |
| 2026-11-11 | Martine Zimmermann | Independent Director | Intent to Sell (Form 144) | -2,000 | $318.17 |
| 2026-11-10 | John Kozarich | Independent Chairperson | Intent to Sell (Form 144) | -500 | $317.32 |
| 2026-11-09 | Jason Aryeh | Independent Director | Open Market Disposition | -3,000 | $319.99–320.20 |
| 2026-11-03 | Jason Aryeh | Independent Director | Open Market Disposition | -282 | $319.99 |
| 2026-11-01 | Jason Aryeh | Independent Director | Open Market Disposition | -2,111 | $317.74–320.49 |
| 2026-11-01 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -700 | $316.56 |
| 2026-11-01 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–323.14 |
| 2026-10-29 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -1,209 | $318.60 |
| 2026-10-29 | Jason Aryeh | Independent Director | Intent to Sell (Form 144) | -202 | $320.49 |
| 2026-10-01 | Andrew Reardon | Chief Legal Officer | Automatic Disposition | -4,660 | $302.51–307.74 |
| 2026-10-01 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -340 | $52.27–302.51 |
| 2026-09-21 | Martine Zimmermann | Independent Director | Sale to Issuer | -115 | $298.50 |
| 2026-09-09 | Martine Zimmermann | Independent Director | Open Market Disposition | -1,200 | $285.00 |
| 2026-09-02 | Andrew Reardon | Chief Legal Officer | Automatic Disposition | -5,000 | $283.99–288.98 |
| 2026-08-11 | Jason Haas | Independent Director | Open Market Disposition | -1,000 | $292.81 |
| 2026-08-11 | Jason Haas | Independent Director | Derivative Exercise and Sale | -6,138 | $51.56–292.81 |
| 2026-08-11 | Octavio Espinoza | Chief Financial Officer | Derivative Exercise and Sale | -31,641 | $52.84–292.07 |
| 2026-08-02 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–292.82 |
| 2026-06-30 | Andrew Reardon | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $52.27–317.15 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ligand Pharmaceuticals discussion 0 comments